Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Nanomedicine (Lond). 2012 Jun 18;7(10):1507–1519. doi: 10.2217/nnm.12.27

Figure 4. In vivo MRI study of pre- and post-treatment with targeted fumagillin prodrug nanoparticles.

Figure 4

In vivo MR signal enhancement post-treatment with (A & B) targeted fumagillin nanoparticles and (C & D) control (no drug). In the pre-treatment images, areas of Matrigel™ implantation have been marked with yellow arrows. In the post-treatment images, signal enhancement has been denoted with orange arrows. (E) Reduced Matrigel implant enhancement in rats treated with αvβ3-integrin-targeted nanoparticles with fumagillin-PD versus αvβ3-integrin-targeted nanoparticles with fumagillin, αvβ3-integrin-targeted nanoparticles without drug and nontargeted nanoparticles with fumagillin-PD.

NT: Nontargeted; PD: Prodrug.